Javier Munoz, MD MS MBA

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Pharmacyclics/Abbvie, Bayer, Gilead/Kite, Beigene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genzyme, Genentech/Roche, ADC Therapeutics, Epizyme, Beigene, Novartis, Morphosys/Incyte
    Topic:
    Consulting
    Date added:
    06/11/2024
    Date updated:
    06/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    MEI, TG Therapeutics, AstraZeneca, Eli Lilly
    Topic:
    Consulting
    Date added:
    06/11/2024
    Date updated:
    06/11/2024
  • Type of financial relationship:
    Financial Support
    Ineligible company:
    Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, Beigene
    Topic:
    Research funding
    Date added:
    06/11/2024
    Date updated:
    06/11/2024
  • Type of financial relationship:
    Other
    Ineligible company:
    Targeted Oncology, OncView, Curio, and Physicians' Education Resource
    Topic:
    Honoraria
    Date added:
    06/11/2024
    Date updated:
    06/11/2024
Return to Best of Hematology and Breast Cancer 2025, Phoenix